SCYNEXIS to Participate in H. C. Wainwright 26th Annual Global Investment Conference
SCYNEXIS (NASDAQ: SCYX), a biotechnology company focused on developing innovative medicines for difficult-to-treat and drug-resistant infections, has announced its participation in the H. C. Wainwright 26th Annual Global Investment Conference. The event is scheduled for September 11, 2024, in New York City.
David Angulo, M.D., President and CEO of SCYNEXIS, will deliver a corporate presentation at 10:00 A.M. ET and will be available for one-on-one meetings with investors. Interested parties can request meetings through their H.C. Wainwright representative. The presentation will also be accessible via a live webcast, providing an opportunity for remote participation.
SCYNEXIS (NASDAQ: SCYX), un azienda biotecnologica focalizzata sullo sviluppo di farmaci innovativi per infezioni difficili da trattare e resistenti ai farmaci, ha annunciato la sua partecipazione alla 26ª Conferenza Annuale di Investimento Globale H. C. Wainwright. L'evento è programmato per l'11 settembre 2024, a New York City.
David Angulo, M.D., Presidente e Amministratore Delegato di SCYNEXIS, terrà una presentazione aziendale alle 10:00 A.M. ET e sarà disponibile per incontri individuali con gli investitori. Le parti interessate possono richiedere incontri tramite il loro rappresentante H.C. Wainwright. La presentazione sarà disponibile anche tramite una webcast dal vivo, offrendo un'opportunità di partecipazione remota.
SCYNEXIS (NASDAQ: SCYX), una empresa de biotecnología centrada en el desarrollo de medicamentos innovadores para infecciones difíciles de tratar y resistentes a los fármacos, ha anunciado su participación en la 26ª Conferencia Anual de Inversión Global H. C. Wainwright. El evento está programado para el 11 de septiembre de 2024, en la ciudad de Nueva York.
David Angulo, M.D., Presidente y CEO de SCYNEXIS, realizará una presentación corporativa a las 10:00 A.M. ET y estará disponible para reuniones uno a uno con inversores. Las partes interesadas pueden solicitar reuniones a través de su representante de H.C. Wainwright. La presentación también estará disponible a través de una transmisión en vivo, proporcionando una oportunidad para la participación remota.
SCYNEXIS (NASDAQ: SCYX)는 치료하기 어려운 약물 내성 감염을 위한 혁신적인 의약품 개발에 집중하는 생명공학 회사로, H. C. Wainwright 제26회 연례 글로벌 투자 컨퍼런스에 참가할 것이라고 발표했습니다. 이 행사는 2024년 9월 11일에 뉴욕시에서 개최될 예정입니다.
David Angulo, M.D., SCYNEXIS의 사장 겸 CEO가 오전 10시 (ET)에 기업 프레젠테이션을 진행하며, 투자자들과의 일대일 미팅도 가능합니다. 관심 있는 분들은 H.C. Wainwright 대표를 통해 미팅을 요청할 수 있습니다. 발표는 실시간 웹캐스트를 통해서도 접근할 수 있어 원격 참여의 기회를 제공합니다.
SCYNEXIS (NASDAQ: SCYX), une entreprise de biotechnologie axée sur le développement de médicaments innovants pour traiter des infections difficiles et résistantes aux médicaments, a annoncé sa participation à la 26ème Conférence Annuelle d'Investissement Mondial H. C. Wainwright. L'événement est prévu pour le 11 septembre 2024, à New York City.
David Angulo, M.D., Président et CEO de SCYNEXIS, fera une présentation d'entreprise à 10h00 ET et sera disponible pour des réunions individuelles avec les investisseurs. Les parties intéressées peuvent demander des réunions par l'intermédiaire de leur représentant H.C. Wainwright. La présentation sera également accessible via un webinaire en direct, offrant une opportunité de participation à distance.
SCYNEXIS (NASDAQ: SCYX), ein Biotechnologieunternehmen, das sich auf die Entwicklung innovativer Arzneimittel für schwer behandelbare und arzneimittelresistente Infektionen konzentriert, hat seine Teilnahme an der 26. jährlichen globalen Investorenkonferenz von H. C. Wainwright angekündigt. Die Veranstaltung ist für den 11. September 2024 in New York City angesetzt.
David Angulo, M.D., Präsident und CEO von SCYNEXIS, wird um 10:00 Uhr ET eine Unternehmenspräsentation halten und steht für persönliche Gespräche mit Investoren zur Verfügung. Interessierte Parteien können über ihren H.C. Wainwright-Vertreter Meetings anfragen. Die Präsentation wird auch über eine Live-Webcast verfügbar sein, was eine Möglichkeit zur Fernteilnahme bietet.
- None.
- None.
JERSEY CITY, N.J., Aug. 27, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced David Angulo, M.D., President and Chief Executive Officer, will make a corporate presentation as well as host 1x1 meetings at the H. C. Wainwright 26th Annual Global Investment Conference on Wednesday, September 11 at 10:00 A.M. ET.
H. C. Wainwright 26th Annual Global Investment Conference
| Format: | Live presentation and one-on-one meetings |
| Date: | Wednesday, September 11, 2024 |
| Time: | 10:00 A.M. ET |
| Location: | New York, NY |
| Webcast: | Link |
To request a one-on-one meeting with management, please reach out to your H.C. Wainwright representative.
About SCYNEXIS
SCYNEXIS, Inc. (NASDAQ: SCYX) is a biotechnology company pioneering innovative medicines to help millions of patients worldwide overcome and prevent difficult-to-treat infections that are becoming increasingly drug-resistant. SCYNEXIS is developing the company’s proprietary antifungal platform “fungerps”. Ibrexafungerp, the first representative of this novel class, has been licensed to GSK. The U.S. Food and Drug Administration (FDA) approved BREXAFEMME® (ibrexafungerp tablets) in June 2021, for its first indication in vulvovaginal candidiasis (VVC), followed by a second indication in November 2022, for reduction in the incidence of recurrent VVC. Late-stage clinical investigation of ibrexafungerp for the treatment of life-threatening invasive fungal infections in hospitalized patients is ongoing. Additional antifungal assets from this novel class are currently in pre-clinical and discovery phase, including the compound SCY-247. For more information, visit www.scynexis.com.
CONTACT:
Investor Relations
Irina Koffler
LifeSci Advisors
Tel: (646) 970-4681
ikoffler@lifesciadvisors.com
FAQ
When is SCYNEXIS (SCYX) presenting at the H. C. Wainwright Global Investment Conference?
Who will be representing SCYNEXIS (SCYX) at the H. C. Wainwright conference?
What type of meetings will SCYNEXIS (SCYX) be hosting at the investment conference?
Where is the H. C. Wainwright Global Investment Conference being held?
Will there be a webcast of SCYNEXIS's (SCYX) presentation at the conference?
